AI x Bio's Wild 48 Hours: AI-Designed Phage in a Patient, OpenAI Buys Orchestra Bio
AllThingsApx · x · 2026-10-22
A roundup of a remarkable 48-hour run for AI in biology: Omnii-1 became the first AI-designed phage therapy given to a patient; Claude was used to design scorpion toxin binders; OpenAI acquired Orchestra Bio and partnered with PerturbAI on agents that found brain-disease clues.
Other notable items: Baker Lab released RFD4-Proteina, Chaperone shipped an agent framework for protein design, BioEmu2 launched for protein simulations, Artios introduced an enzyme design model, and Xaira unveiled X-Scientist.
More from Venture
- YC President Amplifies Founder's Take: Team Matters Far More Than Imagined Moats — garrytan · 2026-10-22
- Brex data names fastest-growing startups: Greptile, Blacksmith and PostHog lead — ycombinator · 2026-10-22
- Larry Page reportedly moves into $173M Miami home to dodge $15B California tax bill — 4KTV · 2026-10-22
- Meta set to post 23.6% revenue growth to $63.3B in Q3, but capex seen jumping 115% — Beth_Kindig · 2026-10-22
- DeepSeek-driven token flood puts the $2T inference growth story at risk — ivan_bezdomny · 2026-10-22
- The Gap in AI Consulting: Advisors Who Go Deep and Still Speak Human — EXM7777 · 2026-10-22